CC Chemokine Receptor 3 Antibodies

CCR3 (C-C Chemokine Receptor Type 3) is a G protein-coupled receptor that primarily binds to chemokines such as eotaxin (CCL11), RANTES (CCL5), and MCP-3 (CCL7). It plays a key role in the regulation of immune responses, particularly in the recruitment and activation of eosinophils, basophils, and Th2 lymphocytes. CCR3 is predominantly expressed on eosinophils and basophils, and to a lesser extent on Th2 cells, mast cells, and airway epithelial cells. Its expression is especially prominent in tissues involved in allergic inflammation, such as the lungs in asthma. CCR3 is considered a potential pharmacological target for the treatment of allergic diseases and conditions involving eosinophilic inflammation, such as asthma, allergic rhinitis, and eosinophilic esophagitis. While several CCR3 antagonists have been developed and tested in preclinical and early clinical studies, none have yet reached widespread clinical use, in part due to challenges in achieving effective and selective inhibition. For more information on CCR3 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.